

Submitted by:

Etay Ziv, MD, PhD, Memorial Sloan Kettering Cancer Center Nicholas Fidelman, MD, University of California San Francisco Rony Avritscher, MD, UT MD Anderson Cancer Center

Organization: Society of Interventional Oncology 2001 K Street, 3rd Floor, Washington, DC 20006

Phone (202) 367-1164 Email: tgreene@sio-central.org

September 14, 2021

NCCN Guidelines Panel: Neuroendocrine and Adrenal Tumors

On behalf of the Society of Interventional Oncology, we respectfully request the NCCN Neuroendocrine and Adrenal Tumors guideline panel review the enclosed recommendations:

Specific change 1: NET-10: In NET-7, guidelines state for localized disease, "if surgery contraindicated, thermal ablation or SBRT." However, in NET-10, for unresectable low grade or intermediate grade there is no mention of thermal ablation as an option. Thermal ablation should be added as an option for consistency with NET-7.

<u>Specific change 2:</u> Pheo-2: Under distant metastases, please include liver directed therapy for liver dominant disease with reference to principles of liver directed therapy.

Thank you for your consideration,

Etay Ziv, MD, PhD Nicholas Fidelman, MD Rony Avritscher, MD Matthew Callstrom, MD, PhD President Mayo Clinic

Muneeb Ahmed, MD President-Elect

Beth Israel Deaconess Medical Center/Harvard

> William Rilling, MD, FSIR Immediate Past President Medical College of Wisconsin

Alexis Kelekis, MD Treasurer Attikon University Hospital Athens

Jack Jennings, MD, PhD Washington University School of Medicine

Edward Kim, MD, FSIR Mount Sinai Health System

Martijn Meijerink, MD, PhD Amsterdam UMC

Uei Pua, MBBS Tan Tock Seng Hospital

Constantinos T.
Sofocleous, MD, PhD,
FSIR, FCIRSE
Memorial SloanKettering Cancer Center

Sarah White, MD, MS Medical College of Wisconsin

Ex-Officio
Michael C. Soulen, MD
Research Advisor
Hospital of the University
of Pennsylvania

Executive Director
Jena Eberly Stack

